Home page News Related Researches 2020-2029

Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical Cancer

Published on Friday, 24 October 2025

Abstract

BACKGROUND: Cervical cancer is the fourth most common cancer among women. The case fatality rate of advanced-stage cervical cancer was approximately 50% in 2020 worldwide. A new approach to finding a better treatment outcome for advanced-stage cervical cancer is needed. Research findings showed that cholecalciferol may benefit cancer cell control. This study aimed to understand the impact of cholecalciferol supplementation on advanced-stage cervical cancer treatment by radiotherapy.

MATERIAL AND METHODS: A randomized controlled trial with a pretest-posttest control group design was conducted between 2021 and 2023 at Dr. Hasan Sadikin Hospital, Bandung, Indonesia. Eligible consecutive patients were recruited and randomly assigned to either the Treatment or Control group using a simple randomization method. The Treatment group received 10 000 IU of cholecalciferol daily for 7 weeks during radiotherapy and for 12 weeks after treatment, while the Control group received a placebo in addition to the same radiotherapy protocol. Clinical outcomes were assessed 3 months after treatment completion.

RESULTS: We recruited 123 subjects in this study. The complete response rate was 82.61% in the Treatment group and 64.8% in the Control group. The Treatment group had a higher average serum cholecalciferol level after completion of the protocol.

CONCLUSIONS: Supplementation with 10 000 IU of cholecalciferol among advanced-stage cervical cancer patients undergoing radiotherapy treatment resulted in improved therapeutic response and maintaining serum cholecalciferol levels, which mayfurther benefit cancer-free survival.

Download the complete article

About this publication.

- The Di Bella Method (A Fixed Part - Dihydrotachysterol, Alfacalcidol, synthetic Vitamin D3);

- Vitamin D (analogues and/or derivatives) and cancer - In vitro, review and in vivo publications;

- The Di Bella Method (A Fixed Part - Calcium, 2 grams per day, orally);

The Di Bella's Method: Use of Vitamin D analogues and/or derivatives - together with others chemical compounds - in several Oncological Pathologies:

- A retrospective observational clinical study of triple negative breast cancer cases treated with Di Bella Method: A preliminary data;

- The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer;

- Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness;

- Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;

- Chronic Lymphocytic Leukemia: Long-Lasting Remission with Combination of Cyclophosphamide, Somatostatin, Bromocriptine, Retinoids, Melatonin, and ACTH;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;